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INTRODUCTION
The widespread use of antimicrobial compounds 
has contributed to the emergence of Staphylococcus 
aureus strains resistant to several antimicrobial groups, 
including new compounds 21 . Linezolid is the first an-
timicrobial of the oxazolidinone group, available since 
2000. It interferes with protein synthesis by binding 
to the bacterial 50S ribosomal subunit. It’s currently 
used for treatment of methicillin-susceptible and meth-
icillin-resistant S. aureus (MSSA and MRSA, respec-
tively) infections and vancomycin-resistant enterococci 
(VRE) 1 . 
The linezolid surveillance network which moni-
tored european medical centers for eight years (2002-
2009) reported the emergence of linezolid-resistant 
bacteria in Ireland in 2007, France and Italy in 2006-
2009, Germany in 2006, 2008 and 2009, Sweden in 
2008 and United Kingdom in 2008 20 . In the hospital 
environment, linezolid-resistant MRSA 13 and linezol-
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id-resistant VRE 11 emerged soon after its approval in 
2000.
In addition to antimicrobial resistance traits, S. au-
reus may present a wide array of cell-surface and se-
cretory virulence factors which may strongly influence 
infection outcome. They include surface adhesins that 
promote bacterial binding to the host 8 , biofilm that can 
protect the bacterial community from antimicrobials’ 
action and host immune defences 16 , and lipases, prote-
ases, hyaluronidases and nucleases which contribute to 
tissue destruction 6 .
Several clinical cases of linezolid-resistant MRSA 
have been reported worldwide 10, 13, but to our knowl-
edge, this is the first description of a linezolid-resistant 
MRSA from animal origin in Portugal. 
MATERIALS AND METHODS
A Rottweiler dog five year old with a history of re-
current otitis was carried to the Teaching Hospital of the 
Faculty of Veterinary Medicine, Technical University 
of Lisboa (FMV/UTL). Treatment with amoxicillin-
clavulanate (22 mg/kg, SQ, q24h) had been prescribed, 
for 15 days, without clinical success. The patient re-
turned with a severe bilateral hypertrophic otitis with 
stenosis of the ear canal. Enrofloxacin (10 mg/kg, SQ, 
q24h), and prednisolone (1 mg/kg, p.o., q12h) were then 
prescribed, for eight days, also without clinical success. 
Ear swabs were taken from both ears for bacteriol-
ogy and antimicrobial susceptibility testing. The dog 
was medicated the same day with topic chlorampheni-
col for 20 days. Given the laboratory results and poor 
clinical improvement, both ear canals were surgically 
removed.
Ear swabs were plated directed onto Columbia 
supplemented with 5% sheep blood (BioMérieux), and 
MacConkey agar plates (Merck) incubated for 24 to 48 
hours at 37ºC under aerobic atmosphere. Enrichment 
cultures were performed (Brain heart infusion broth, 
BHIB, Difco), to allow the detection of more fastidious 
microorganisms. For strict anaerobes, samples were 
plated directed onto Schaedler agar plates (BioMéri-
eux) and incubated for 48 hours at 37ºC in the absence 
of oxygen, using an anaerobic jar (Anaerobic System, 
BioMérieux). Bacterial identification was performed 
using the API20E system (BioMérieux) and confirmed 
by PCR amplification as described by Pereira et al.18 .
Antimicrobial susceptibility testing was performed 
by the disc diffusion method, according to the Clini-
cal and Laboratory Standards Institute recommenda-
tions 3 : Aminoglycosides (amikacin 30 µg, gentamicin 
10 µg, kanamycin 30 µg, neomycin 10 µg, streptomycin 
10 µg, tobramycin 10 µg), carbapenems (imipenem 10 
µg), first generation cephalosporins (cephazolin 30 µg, 
cephalexin 30 µg), second generation cephalosporins 
(cefoxitin 30 µg), third generation cephalosporins (ce-
foperazone 75 µg, cephotaxime 30 µg), glycopeptides 
(vancomycin 30 µg), lincosamides (clindamycin 2 µg, 
lincomycin 2 µg), macrolides (erythromycin 15 µg), 
penicillins (cloxacillin 5 µg, oxacillin 1 µg, penicillin 
G 10 U) and penicillin combinations (amoxicillin-cla-
vulanate 30 µg), fluoroquinolones (ciprofloxacin 5 µg, 
enrofloxacin 5 µg, nalidixic acid 30 µg, norfloxacin 10 
µg), oxazolidinones (linezolid 30 µg), phenicols (chlor-
amphenicol 30 µg), sulphonamides (sulphamethoxa-
zole-trimethoprim, 25 µg), tetracyclines (tetracycline 
30 µg), and fusidic acid (10 µg) were used. All discs 
were purchased from Oxoid. PCR amplification was 
performed to confirm the presence of mecA gene 18 . 
Virulence phenotypic characterization was also per-
formed, as follows:
-Haemolytic activity-isolate was plated onto Co-
lumbia agar supplemented with 5% sheep blood (Bio-
Mérieux) and incubated at 37°C for 48 h under aerobic 
conditions. The presence of a transparent halo sur-
rounding the colonies was registered as ß-hemolysis 19 .
-Gelatinase activity-isolate was plated onto gelati-
nase test agar (Liofilchem). After incubation for 48 h 
at 37ºC, the plate was flooded with a saturated solution 
of ammonium sulphate. A positive result was revealed 
by the presence of a transparent halo around bacterial 
colonies 22 .
-Deoxyribonuclease activity-isolate was plated onto 
DNase test agar (Liofilchem). After an incubation of 48 
h at 37ºC, the plate was flooded with hydrochloric acid 
(1N). Positive DNase activity was revealed by the pres-
ence of clear zone around bacterial colonies 25 .
-Biofilm production-isolate was plated onto Congo 
red agar (Sigma-Aldrich) and the plate was incubated 
for 24 h at 37ºC. Biofilm producer isolates originate 
black colonies, while non-producers remain red 9 .
-Coagulase activity-isolate was inoculated in BHIB 
and incubated at 37°C for 24h. A volume of 100 µl of 
the broth culture was added to 300 µl of EDTA rabbit 
plasma (VWR) and incubated at 37°C for 24 h. Coagu-
lase activity was revealed by gel formation 23 .
RESULTS AND DISCUSSION
This report describes a case of a severe bilateral oti-
tis in a dog caused by linezolid-resistant MRSA. The 
dog had a history of otitis for two months and had been 
subjected to three therapeutic protocols before bacte-
riological and antimicrobial susceptibility tests here 
done. Laboratory results showed that the infection was 
caused by S. aureus, isolated in pure culture. Staphy-
lococci are the most common bacteria responsible of 
canine otitis. Antimicrobial resistance of staphylococci 
isolated from dog’s ear is frequent and a high percent-
age of the isolates are multiresistant 14, 17 . 
In our study, a wide range of antimicrobials was 
tested, and the isolate only revealed susceptibility to 
chloramphenicol, fusidic acid, linezolid and vancomy-
cin. The emergence of multiresistant strains require 
different therapeutic strategies to overcome selective 
pressure while improving clinical success. Some of the 
“old” antimicrobials have not been widely use in recent 
years, being active against a large number of prevalent 
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bacterial isolates 7, 15 . Chloramphenicol and fusidic acid 
are examples of re-emerging compounds for treatment 
of multidrug resistance bacteria, being inexpensive al-
ternatives for the treatment of MRSA infections 7, 15 . 
The strategy of using new or last-generation com-
pounds should be carefully taken into consideration, 
weighing the risk of inducing antimicrobial resistance 
versus the need for medical care. Linezolid and van-
comycin are newer compounds used as “last resource” 
for the treatment of MRSA infections in humans. Al-
though the majority of the staphylococcal isolates from 
animal source remain susceptible to these drugs 2 , they 
are not licensed for veterinary use and could cause ad-
verse reactions or have poor pharmacokinetic in small 
animals 5 which leave veterinary clinicians with little 
therapeutical options. Resistance to linezolid among 
MRSA is reported to be very rare 21 , but the isolate 
studied showed to be resistant to this drug.
S. aureus possesses a wide array of virulence fac-
tors, including extracellular toxins and surface struc-
tures that facilitate immune evasion, tissue coloniza-
tion and destruction 24 . The isolate under study was 
β-haemolytic, coagulase-positive and DNAse and 
gelatinase producer. The production of exo-enzymes 
has been reported among S. aureus from different 
sources 4, 12 and has been related to bacterial virulence. 
This isolate did not express biofilm, another recognized 
virulence factor in staphylococci, which is in agreement 
with previous studies that showed that biofilm produc-
tion is more prevalent in MSSA than in MRSA 24 .
Taken together, the results suggest that this isolate 
has an increased ability to colonize and cause tissular 
disruption and is resistant to all available antimicro-
bials licensed for veterinary medicine. Linezolid-re-
sistance outbreaks in human medical centers are be-
coming more frequently reported worldwide 10 , rising 
concerns about human and animal health safety. To our 
knowledge, this is the first report of a linezolid-resis-
tant MRSA isolated from an animal source. Multidrug 
linezolid-resistant MRSA from animal origin are chal-
lenge to practitioners and the spread of this strain may 
be of worldwide concern. 
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